{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:25:14Z","timestamp":1763468714868},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Non-immunoglobulin E (IgE)-mediated hypersensitivity reactions (HSRs) to nafcillin are commonly reported, but scarce data are available to guide appropriate antibiotic change following these reactions. Although cefazolin is an attractive therapeutic alternative in methicillin-susceptible Staphylococcus aureus (MSSA) infections when patients experience an HSR to nafcillin, more data are needed to evaluate the tolerability of cefazolin after switching from nafcillin. The purpose of this study was to describe the tolerability of cefazolin in patients who develop a suspected non-IgE-mediated HSR to nafcillin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, descriptive case series of patients who received nafcillin for an MSSA infection, experienced a suspected non-IgE-mediated HSR, and were switched to cefazolin between October 2015 and November 2019 at a single academic medical center. The primary objective was to identify the percentage of patients who completed cefazolin after experiencing a suspected non-IgE-mediated HSR to nafcillin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 80 patients with 87 prespecified non-IgE-mediated HSRs during the study period. Seventy-one (89%) patients completed cefazolin, with 53 (75%) of these patients completing at least 2 weeks of therapy. One patient was ultimately switched from cefazolin to daptomycin due to concern for treatment failure. Eight patients (10%) did not tolerate cefazolin after switching from nafcillin. Of these, 3 patients experienced an unrelated HSR, whereas 5 patients experienced the same non-IgE-mediated HSR that was attributed to nafcillin and discontinued cefazolin within 7 days. The most common HSR cited was immune-mediated nephritis; however, the majority were clinically presumed but did not meet objective diagnostic criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Treatment with cefazolin after experiencing a suspected non-IgE-mediated HSR to nafcillin appears to be safe, even for patients requiring a prolonged duration of cefazolin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab368","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:40:11Z","timestamp":1619138411000},"page":"1650-1655","source":"Crossref","is-referenced-by-count":7,"title":["Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible <i>Staphylococcus aureus<\/i> Infections"],"prefix":"10.1093","volume":"73","author":[{"given":"Ankit M","family":"Gandhi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Virginia Health, Charlottesville, Virginia, USA"},{"name":"National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan D","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Virginia Health, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay E","family":"Donohue","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Virginia Health, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather L","family":"Cox","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Virginia Health, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua C","family":"Eby","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia Health, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"key":"2022020900142374800_CIT0001","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.anai.2010.08.002","article-title":"Drug allergy: an updated practice parameter","volume":"105","author":"Solensky","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2022020900142374800_CIT0002","article-title":"Penicillin allergy. [Updated 2019 Apr 23]","volume-title":"StatPearls","author":"Patterson","year":"2020"},{"key":"2022020900142374800_CIT0003","first-page":"317","article-title":"The classification of allergic reactions underlying disease.","volume-title":"Clinical aspects of immunology","author":"Gell","year":"1963","edition":"1"},{"key":"2022020900142374800_CIT0004","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"2022020900142374800_CIT0005","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/ncpneph0561","article-title":"Four cases of nafcillin-associated acute interstitial nephritis in one institution","volume":"3","author":"Hoppes","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"2022020900142374800_CIT0006","doi-asserted-by":"crossref","first-page":"953714","DOI":"10.1155\/2012\/953714","article-title":"A fatal case of nafcillin-induced hepatotoxicity: a case report and the literature review","volume":"2012","author":"Alam","year":"2012","journal-title":"Case Rep Med"},{"key":"2022020900142374800_CIT0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ndt\/gfg464","article-title":"The changing profile of acute tubulointerstitial nephritis","volume":"19","author":"Baker","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2022020900142374800_CIT0008","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","article-title":"Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Schweizer","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2022020900142374800_CIT0009","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1086\/510386","article-title":"Use of vancomycin of first generation cephalosporins for the treatment of hemodialysis dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia","volume":"44","author":"Stryjewski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2022020900142374800_CIT0010","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1681\/ASN.2012010050","article-title":"Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD","volume":"23","author":"Chan","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022020900142374800_CIT0011","first-page":"106","article-title":"Cephalosporins can be prescribed safely for penicillin-allergic patients","volume":"55","author":"Pichichero","year":"2006","journal-title":"J Fam Pract"},{"key":"2022020900142374800_CIT0012","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.diagmicrobio.2006.12.004","article-title":"Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift","volume":"57","author":"Pichichero","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022020900142374800_CIT0013","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1128\/AAC.02504-13","article-title":"Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting","volume":"58","author":"Blumenthal","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2022020900142374800_CIT0014","first-page":"100","article-title":"Cefazolin use in patients who report a non-IgE mediated penicillin allergy: a retrospective look at adverse reactions in arthroplasty","volume":"32","author":"Haslam","year":"2012","journal-title":"Iowa Orthop J"},{"key":"2022020900142374800_CIT0015","first-page":"2527","article-title":"Diagnosis and management of acute interstitial nephritis","volume":"67","author":"Kodner","year":"2003","journal-title":"Am Fam Physician"},{"key":"2022020900142374800_CIT0016","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archinte.1978.03630310009008","article-title":"Adverse reactions to methicillin and nafcillin during treatment of serious Staphylococcus aureus infections","volume":"138","author":"Kancir","year":"1978","journal-title":"Arch Intern Med"},{"key":"2022020900142374800_CIT0017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2022020900142374800_CIT0018","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022020900142374800_CIT0019","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/1060028019897267","article-title":"Retrospective analysis of adverse drug events between nafcillin versus cefazolin for treatment of methicillin-susceptible Staphylococcus aureus infections","volume":"54","author":"Chan","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2022020900142374800_CIT0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","article-title":"The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"6","author":"Flynt","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2022020900142374800_CIT0021","first-page":"472","article-title":"Absence of nafcillin-associated nephritis: a prospective analysis of 210 patients","volume":"133","author":"Barriere","year":"1980","journal-title":"West J Med"},{"key":"2022020900142374800_CIT0022","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ckj\/sfs160","article-title":"The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review","volume":"6","author":"Lopes","year":"2013","journal-title":"Clin Kidney J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab368\/38858986\/ciab368.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/1650\/42388514\/ciab368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/9\/1650\/42388514\/ciab368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:28:44Z","timestamp":1644366524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/9\/1650\/6255689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,4,27]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab368","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,4,27]]}}}